Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VVD-159642 in Advanced Solid Tumors
NCT06804824Phase 1Recruiting
- Sponsor
- Vividion Therapeutics
- Start
- Feb 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of VVD-159642 in solid tumor (advanced stage) (4 arms), sponsored by Vividion Therapeutics. Primary endpoints: Dose-limiting Toxicities at 21 days, Adverse Events and Serious Adverse Events at 29 months and 2 more. Started Feb 2025; status: recruiting.
02
Drugs
VVD-159642
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06804824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06804824.